A prospective observational, cohort-based, cross-sectional study to analyse ophthalmological adverse events associated with Pimasertib
Latest Information Update: 05 Feb 2019
At a glance
- Drugs Pimasertib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
Most Recent Events
- 05 Feb 2019 New trial record